Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 5/20 | 0.55 |
| ▸ | KIT | P10721 | 3/20 | 0.38 |
| ▸ | PI4KA | P42356 | 1/20 | 0.32 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.32 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.32 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.32 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.32 |
| ▸ | EGFR | P00533 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL179556 | 0.75 | MAP4K4 (0.34) | MAP4K4PDE10A | |
| SCHEMBL179557 | 0.75 | MAP4K4 (0.34) | MAP4K4PDE10A | |
| SCHEMBL58274 | 0.71 | MAP4K4 (1.00) | MAP4K4KITPDE10AEGFR | |
| SCHEMBL12395323 | 0.71 | MAP4K4 (0.32) | MAP4K4 | |
| Hydrochloric Acid SCHEMBL15019896 | 0.69 | MAP4K4 (0.96) | MAP4K4KITPDE10AEGFR | |
| SCHEMBL20299311 | 0.67 | SMPD3 (0.37) | MAP4K4 | |
| SCHEMBL21362941 | 0.66 | MAP4K4 (0.33) | MAP4K4 | |
| SCHEMBL275263 | 0.64 | MAP4K4 (0.47) | MAP4K4KITPI4KAPI4K2BPI4K2A | |
| SCHEMBL19698007 | 0.64 | MAP4K4 (0.47) | MAP4K4KITPI4KAPI4K2BPI4K2A | |
| SCHEMBL13075093 | 0.64 | MAP4K4 (0.47) | MAP4K4KIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120118089-A | BTK inhibitors | 迪哲(江苏)医药股份有限公司 | 2025-06-10 | — | — | CN | claimed |
| CN-114945574-B | BTK inhibitors | 迪哲(江苏)医药股份有限公司 | 2025-02-07 | — | — | CN | claimed |
| EP-4087845-A1 | BTK INHIBITORS | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2022-11-16 | — | — | EP | claimed |
| CN-114945574-A | BTK inhibitors | 迪哲(江苏)医药股份有限公司 | 2022-08-26 | — | — | CN | claimed |
| US-12624039-B2 | BTK inhibitors | DIZAL (JIANGSU) PHARCEUTICAL CO., LTD. (CN) | 2026-05-12 | — | — | US | disclosed |
| CN-120118089-A | BTK inhibitors | 迪哲(江苏)医药股份有限公司 | 2025-06-10 | — | — | CN | disclosed |
| CN-114945574-B | BTK inhibitors | 迪哲(江苏)医药股份有限公司 | 2025-02-07 | — | — | CN | disclosed |
| CN-114634512-B | Compounds as inhibitors of bruton's tyrosine kinase, preparation method and medical application thereof | 江苏恒瑞医药股份有限公司 | 2023-11-14 | — | — | CN | disclosed |
| US-20230122807-A1 | BTK INHIBITORS | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2023-04-20 | — | — | US | disclosed |
| EP-4087845-A1 | BTK INHIBITORS | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2022-11-16 | — | — | EP | disclosed |
| CN-115298180-A | Compounds for treating or inhibiting recurrence of acute myeloid leukemia | 富雷旭医疗有限责任公司 | 2022-11-04 | — | — | CN | disclosed |
| CN-114945574-A | BTK inhibitors | 迪哲(江苏)医药股份有限公司 | 2022-08-26 | — | — | CN | disclosed |
| EP-1740591-B1 | 6,6-BICYCLIC RING SUBSTITUTED HETEROBICYCLIC PROTEIN KINASE INHIBITORS | OSI PHARM INC (US) | 2009-06-17 | — | — | EP | disclosed |
| US-7534797-B2 | 6,6-Bicyclic ring substituted heterobicyclic protein kinase inhibitors | OSI PHARMACEUTICALS, INC. (US) | 2009-05-19 | — | — | US | disclosed |
| US-20090118499-A1 | 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors | OSI PHARMACEUTICALS, INC. | 2009-05-07 | — | — | US | disclosed |
| US-20090118499-A1 | 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors | OSI PHARMACEUTICALS, INC. | 2009-05-07 | — | — | US | disclosed |
| US-20070149521-A1 | Bicyclic protein kinase inhibitors | OSI PHARMACEUTICALS, INC. | 2007-06-28 | — | — | US | disclosed |
| US-20070149521-A1 | Bicyclic protein kinase inhibitors | OSI PHARMACEUTICALS, INC. | 2007-06-28 | — | — | US | disclosed |
| WO-2007064993-A2 | BICYCLIC PROTEIN KINASE INHIBITORS | OSI PHARMACEUTICALS, INC. (US) | 2007-06-07 | — | — | WO | disclosed |
| US-20060235031-A1 | 6,6-Bicyclic ring substituted heterobicyclic protein kinase inhibitors | ACERTA PHARMA B.V. (NL) | 2006-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230122807-A1 | BTK INHIBITORS | BTK, SYK, LYN | MAP4K4 479/4885KIT 382/4885PI4KA 214/4885 |
| US-20090118499-A1 | 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors | IGF1R, MAP2K7, BRCA1 | MAP4K4 97/4885KIT 739/4885PI4KA 80/4885 |
| US-20070149521-A1 | Bicyclic protein kinase inhibitors | CDK1, MAP4K2, MAP4K3 | MAP4K4 21/4885KIT 1126/4885PI4KA 162/4885 |
| US-20060235031-A1 | 6,6-Bicyclic ring substituted heterobicyclic protein kinase inhibitors | IGF1R, MAP2K7, BRCA1 | MAP4K4 97/4885KIT 739/4885PI4KA 80/4885 |
| US-12624039-B2 | BTK inhibitors | BTK, ABL1, SYK | MAP4K4 932/4885KIT 823/4885PI4KA 301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.